Navigation Links
Endeavor Power Corporation Introduces Its Proprietary FDA Cleared Target System Platform Technology
Date:3/8/2013

CAMBRIDGE, Mass., March 8, 2013 /PRNewswire/ -- Endeavor Power Corporation ("Endeavor Power" or the "Company") (OTCQB: EDVP) introduces its proprietary FDA Cleared Target System Platform Immunoassay Testing Technology ("Target System"). Endeavor Sciences, Inc. ("Endeavor"), the Company's operating wholly owned subsidiarity is pleased to announce the introduction of the Target System, Endeavor's FDA Approved Immunoassay Testing Platform to target the Point-Of-Care Testing (POCT) market.  The Company's diagnostic technology provides a cheaper, more efficient and timely alternative to centralized lab testing and represents a disruptive breakthrough innovation in the bio-medical and healthcare industries.

Endeavor's Target System provides a solution to the soaring costs of healthcare in the US and globally. It will revolutionize and alleviate the decline in revenues of Physicians and the reduction in quality of healthcare service currently available to patients.  A laboratory test that would normally take days for results, can now be performed at the time the patient and healthcare worker interact by utilizing the Target System.  The Target System Solution is modeled on:

  • Reducing the cost of diagnostic tests for patients through reduction of co-pay insurance payments.
  • Reducing the cost of diagnostic tests to medical insurance companies by reducing the cost of the test.
  • Increase the quality of healthcare by providing healthcare workers with results at the time they meet and interact with patients.
  • Provide increased revenue opportunities for Physicians.
  • Provide a simple and easy training process that will allow single process training for those administering the tests.
  • Provide a "Single Platform Solution" for a broad array of tests.
  • Endeavor Target System's high level of sensitivity can detect minute changes in the concentration of analytes necessary to perform difficult immunoassays, while the dynamic range allows resolution to be optimized to suit a full range of frequently ordered diagnostic tests.  This combination of qualitative and quantitative tests on the same platform, allows Endeavor to bring differentiation to the POCT market with a uniquely broad test menu of the following:

  • Controlled Flow-Through Rapid Immunoassay Test
  • Endeavor's US Patent Pending Target System Diagnostics Platform offers an array of improved modifications and features to the traditional Flow-through Immunoassay Test. With its Platform uniformity, patented vacuum pump, absorption layer for sample overflow, and complete compatibility with our optic reader, the Target System Diagnostics Platform is a unique collection of tests for qualitative and quantitative detection of conditions.

  • The Patented Target System "Vacuum Control Flow Device"
  • No other device on the market provides the clinician with "point of care device controls."

    Endeavor's Target System utilizes a patented vacuum and specimen absorption capability built right in. This innovative technology allows for the Target System platform to be utilized for multiple specimen sources including whole blood, serum, plasma, urine and feces.

  • Ease Of Use
  • The patented platform provides tremendous flexibility in sample requirements, clinician training and result interpretation. Our "train once" system means the clinician can now perform a number of single use tests on a wide variety of conditions with the interpretation of results consistent through the platform paradigm.

  • Unlimited Application
  • The unique vacuum pump action reduces test time and ensures maximum contact with the membrane antibodies. This patented collection device is virtually unlimited in the number of different tests that can be incorporated. The company plans to introduce a broad array of tests.

    Endeavor CEO, J. Michael Redmond commented, "The various value propositions created by Endeavor's Target System are quite numerous and I believe allow for Endeavor to have a distinct competitive advantage by allowing for the delivery of superior test results, a capacity for a large number of test interoperability, while you watch rapid test result capability and a simple, proven, robust 'train once' platform that delivers an economy of scale unmatched by our competitors."  Mr. Redmond added further, "We are quite fortunate to start our business with proven technology that is fully developed with 100% regulatory approval to initiate the commercialization of our business. A proven technology allows us to get to market quickly and with significant risk mitigation."

    ABOUT ENDEAVOR POWER CORPORATION Endeavor Power Corp is a fully reporting Nevada corporation traded on the OTCQB under the symbol "EDVP.QB".  The Company is headquartered in Cambridge, MA.  The Company's wholly owned subsidiary Endeavor Sciences, Inc. ("Endeavor") is a bio-medical company focused on infectious diseases, which owns a line of proprietary, FDA approved, Point of Care diagnostic tests on a single proprietary platform.  Endeavor is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians.  Our focus is on tests that detect and/or monitor infectious diseases. The Company's tests combine innovative technologies that provide accessible, practical and rapid point of care in vitro diagnostics are based on the Company's Target System, its FDA Approved Platform that centered on the Target System VT1000, its FDA Approved bench top fluorescence immunoassay spectrum analyzer and its innovative flow through Target System test cartridges. For more information: www.endeavorpowercorp.com and www.endeavorsciences.com

    Forward-Looking Statements

    This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. Media Contact:

    Kyle W. Withrowkylew@endeavorpower.com.com Investor Contact:

    Mark BernhardCapital Group Communicationsmark@capitalgc.com 415.332.7200


    '/>"/>
    SOURCE Endeavor Power Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Drugs.com Launches iOS and Android Mobile App to Empower Patients and Providers Alike
    2. Agent of Change: Ford Empowers Women and Saves Lives in Rural India through New Technology, SUV Capabilities
    3. Leviton Introduces Medical-Grade Power Strips for Use in Patient-Care Areas
    4. Power Wheelchairs Supplier MedSupplyShop.com Highlights Upcoming Changes to Medicare Competitive Bidding Program
    5. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
    6. Varian Medical Systems Supports Program to Tap Brain Power of Research and Development Community in Russia
    7. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
    8. TI introduces lowest-power octal, 100-MSPS ADC for medical, industrial imaging applications
    9. Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment
    10. Free Research Report on Ford Motor Co., Pfizer, Inc., Barclays Bank PLC, General Electric Co. and PowerShares QQQ Trust
    11. Quest Announces Battery-Powered Mobile Wireless Surgical Video Display Solution
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
    (Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
    (Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
    Breaking Medicine Technology:
    (Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
    (Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
    (Date:4/28/2017)... ... 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the ... ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength ... , Removal of the homeopathic element , Adding their ...
    (Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
    (Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to May ... Medicine will host industry leaders for the annual spring Convention & Expo, called ... industry adapt to the issues currently affecting urgent care and on-demand healthcare. , ...
    Breaking Medicine News(10 mins):